Background: Predicting the aggressive behavior of non-functional pancreatic neuroendocrine tumors (NF-PNET) remains controversial. We wanted to explore, in a prospective setting, whether the diagnostic accuracy can be improved by dual-tracer functional imaging Ga-DOTANOC and F-FDG-PET/CT in patients with NF-PNETs.
Methods: Thirty-one patients with NF-PNET (90% asymptomatic) underwent PET-imaging with F-FDG and Ga-DOTANOC, followed by surgery (n = 20), an endoscopic ultrasonography and fine-needle biopsy (n = 2) or follow-up (n = 9). A focal activity on PET/CT greater than the background that could not be identified as physiological activity was considered to indicate tumor tissue. The imaging results were compared to histopathology. The mean follow-up time was 31.3 months.
Results: Thirty-one patients presented a total of 53 lesions (40 histologically confirmed) on PET/CT. Thirty patients had a Ga-DOTANOC-positive tumor (sensitivity 97%) and 10 patients had an F-FDG-positive tumor. In addition, one Ga-DOTANOC-negative patient was F-FDG-positive. F-FDG-PET/CT was positive in 19% (3/16) of the G1 tumors, 63% (5/8) of the G2 tumors and 1/1 of the well-differentiated G3 tumor. Ga-DOTANOC-PET/CT was positive in 94% of the G1 tumors, 100% of the G2 tumors and 1/1 of the well-differentiated G3 tumor. Two out of six (33%) of the patients with lymph node metastases (LN+) were F-FDG-positive. The F-FDG-PET/CT correlated with tumor Ki-67 (P = 0.021). Further, the Krenning score correlated with tumor Ki-67 (P = 0.013). F-FDG-positive tumors were significantly larger than the F-FDG-negative tumors (P = 0.012). F-FDG-PET/CT showed a positive predictive value of 78% in the detection of potentially aggressive tumors (G2, G3, or LN + PNETs); the negative predictive value was 69%.
Conclusions: F-FDG-PET/CT is useful to predict tumor grade but not the LN+ of NF-PNETs. Patients with F-FDG-avid NF-PNETs should be referred for surgery. The Ga-DOTANOC-PET/CT also has prognostic value since the Krenning score predicts the histopathological tumor grade.
Trial Registration: The study has been registered at ClinicalTrials.gov; Non-functional Pancreatic NET and PET imaging, NCT02621541.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928175 | PMC |
| http://dx.doi.org/10.1186/s13550-019-0585-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fibrolamellar hepatocellular carcinoma with intrapancreatic nodal metastases masquerading as pancreatic neuroendocrine tumour with hepatic metastases.
BMJ Case Rep
January 2025
General Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India
Fibrolamellar hepatocellular carcinoma (FL-HCC) is a primary liver tumour presenting at a young age. Aggressive surgery of FL-HCC is the mainstay of management unlike other malignancies where metastatic stage precludes curative surgery. There are limited reports of response of FL-HCC to systemic therapies predominantly owing to its rarity.
View Article and Find Full Text PDFCase study of a neuroendocrine tumor of uncertain origin: single-cell transcriptomics unravels potential primary location.
J Cancer Res Clin Oncol
December 2024
Moscow Clinical Scientific Center N.A. A.S. Loginov, Moscow, 111123, Russia.
Purpose: Determining the primary origin of non-organ-confined neuroendocrine tumors (NETs) for accurate diagnosis and management. Neuroendocrine tumors are rare neoplasms with diverse clinical behaviors. Determining their primary origin remains challenging in cases of non-organ-confined NETs.
View Article and Find Full Text PDFEUS-Guided Radiofrequency Ablation Therapy for Pancreatic Neoplasia.
Diagnostics (Basel)
September 2024
Digestive Endoscopy Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
Radiofrequency ablation (RFA) under endoscopic ultrasound (EUS) guidance has been developed and utilized over the last decade to provide the loco-regional treatment of solid and cystic pancreatic neoplastic lesions. The advantage of this approach relies on the close proximity of the EUS transducer to the target pancreatic lesion, which, coupled with the development of specifically designed RFA ablation devices, has made the procedure minimally invasive, with a clear reduction in adverse events as compared to the high morbidity of the surgical approach. EUS-RFA has been applied so far to pancreatic functional and non-functional neuroendocrine neoplasms, pancreatic ductal adenocarcinoma or metastases to the pancreas, and pancreatic neoplastic cysts.
View Article and Find Full Text PDFSingle-cell sequencing reveals the heterogeneity of pancreatic neuroendocrine tumors under genomic instability and histological grading.
iScience
September 2024
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Article Synopsis
- Histological grading is critical for predicting outcomes, guiding treatment, and evaluating recurrence in non-functional pancreatic neuroendocrine tumors (NF-Pan-NET), with better prognosis in patients lacking copy number variation (CNV).
- The study examined tumor cell heterogeneity based on genomic instability and histological grading, uncovering significant differences in the activated core pathways.
- Key immune cells, such as lymphatic endothelial cells, macrophages, and Treg cells, were identified as contributors to hepatic metastases, enhancing the understanding of NF-Pan-NET's malignant potential.
Non-functional alpha-cell hyperplasia with glucagon-producing NET: a case report.
Front Endocrinol (Lausanne)
September 2024
Unit for Multidisciplinary Research in Biomedicine (UMIB), School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal.
Article Synopsis
- Alpha-cell hyperplasia (ACH) is a rare pancreatic condition with various forms and is often associated with pancreatic neuroendocrine tumors (pNETs), although its causes are not well understood.
- A 72-year-old male with type 2 diabetes was found to have a non-functioning pNET during treatment for gallbladder issues, which revealed mild glucagon elevation and led to surgery.
- Pathological analysis showed the pNET was glucagon-producing and occurred alongside ACH, emphasizing the need for specialized testing to diagnose such cases even when symptoms suggest a non-functioning tumor.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!